August 2025 Capitol Hill Report: Neurology off the Hill

In part two of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss ways to empower professionals in the fields of neurology and research. 

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss strategies for advancing the fields of neurology and neuroscience research. 

Dr. Bakhtawar Ahmad discuss Ellen Grass the founder of the Grass Instruments Company, which played a vital role in the technological development of EEG in this women history minute. 

Dr. Paige Kalika discusses the importance of embracing neurodiversity in medicine.  Show reference:  https://jamanetwork.com/journals/jama/article-abstract/2830611 

Dr. Bradley Ong discusses a newly FDA-approved nasal powder formulation for treating debilitating migraine attacks.

In part two of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss what's new in the diagnosis and treatment of dermatomyositis. 

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss the advancements made over the past decade regarding HMGCR antibody-associated myositis and how to treat it. 

In the September episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost highlight this year's AAN Brain Health Summit and discuss the events taking place.  Show reference:  https://www.aan.com/about-the-aan/presidents-spotlight  https://www.aan.com/tools-resources/brain-health/brain-health-summit  

In the fourth episode of this series, Dr. Andy Southerland discusses the Capitol Hill Report from August 11th, where AAN members met with their local state representatives to discuss making telehealth flexibilities permanent and reforming prior authorization processes. Stay updated with what’s happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In the final part of this series, Dr. Jeff Ratliff and Dr. Valtteri Kaasinen discuss how to speak with patients and families when having a conversation about an initial diagnosis of Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213499